Matrix metalloproteinases in metabolic syndrome

European Journal of Internal Medicine

Volumn 23, Issue 2, 2012, Pages 99-104

  Hopps, E ^a   Caimi, G ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Cardiovascular risk; Matrix metalloproteases; Metabolic syndrome

Indexed keywords

ATORVASTATIN; CANDESARTAN; COLLAGEN; ENALAPRIL; FIBRONECTIN; GELATIN; GELATINASE A; GELATINASE B; IRBESARTAN; LAMININ; LISINOPRIL; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; PIOGLITAZONE; PLASMIN; STROMELYSIN; STROMELYSIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ATHEROSCLEROTIC PLAQUE; BASEMENT MEMBRANE; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIET; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EXERCISE; EXTRACELLULAR MATRIX; HUMAN; HYPERTENSION; LEUKOCYTE ACTIVATION; MACROPHAGE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; REVIEW;

EID: 84856472390     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2011.09.012     Document Type: Short Survey

References (73)

1. M.R. Hayden, J.R. Sowers, and S.C. Tyagi The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded Cardiovasc Diabetol 4 2005 9
2. E. Hopps, D. Noto, G. Caimi, and M.R. Averna A novel component of the metabolic syndrome: the oxidative stress Nutr Metab Cardiovasc Dis 20 2010 72 77
3. A.C. Newby Metalloproteinases expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability Arterioscler Thromb Vasc Biol 28 2008 2108 2114
4. J.D. Raffetto, and R.A. Khalil Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease Biochem Pharmacol 75 2008 346 359 (Pubitemid 350298459)
5. D. Bourbolia, and W.G. Stetler-Stevenson Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion Semin Cancer Biol 20 2010 161 168
6. A. Jaiswal, A. Chhabra, U. Malhotra, S. Kohli, and V. Rani Comparative analysis of human matrix metalloproteinases: emerging therapeutic targets in diseases Bioinformation 6 2011 23 30
7. C. Amalinei, I.D. Caruntu, and R.A. Balan Biology of metalloproteinases Rom J Morphol Embryol 48 2007 323 334
8. Z. Al-Hamodi, I.S. Ismail, R. Saif-Ali, K.A. Ahmed, and S. Muniandy Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects Cardiovasc Diabetol 10 2011 23
9. K. Brew, and H. Nagase The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity Biochim Biophys Acta 1803 2010 55 71
10. F.M. Goncalves, A.L.B. Jacob-Ferreira, V.A. Gomes, A. Casella-Filho, A.C.P. Chagas, and A.M. Marcaccini Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome Clin Chim Acta 403 2009 173 177
11. C.L. Aquilante, A.L. Beitelshees, and I. Zineh Correlates of serum matrix metalloproteinase-8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease Clin Chim Acta 379 2007 48 52 (Pubitemid 46366967)
12. V. Miksztowicz, M.L. Muzzio, M. Royer, M. Prada, R. Wikinski, and L. Scrhreier Increased plasma activity of metalloproteinase 2 in women with metabolic syndrome Metabolism 57 2008 1493 1496
13. C.K. Roberts, D. Won, S. Pruthi, S. Kurtovic, R.K. Sindhu, and N.D. Vaziri Effect of a short-term diet and exercise intervention on oxidative stress, inflammation, MMP-9, and monocyte chemotactic activity in men with metabolic syndrome factors J Appl Physiol 100 2006 1657 1665
14. A. Gummesson, D. Hagg, F.J. Olson, J. Hulthe, L.M. Carlsson, and B. Fagerberg Adipose tissue is not an important source for matrix metalloproteinase-9 in the circulation Scand J Clin Lab Invest 69 2009 636 642
15. A.F. Cicero, G. Derosa, M. Manca, M. Bove, C. Borghi, and A.V. Gaddi Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease Endothelium 14 2007 193 198 (Pubitemid 47543004)
16. M. Lein, L. Nowak, K. Jung, F. Koenig, R. Lichtinghagen, and D. Schnorr Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood Clin Biochem 30 1997 491 496 (Pubitemid 27418546)
17. K. Jung, M. Lein, and A. Roemer Circulating gelatinase B (MMP-9)-the impact of the preanalytical step of blood collection Matrix Biol 21 2002 381 382
18. C. Chavey, B. Mari, M.N. Monthouel, S. Bonnafous, P. Anglard, and E. Van Obberghen Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation J Biol Chem 278 2003 11888 11896 (Pubitemid 36800160)
19. H.R. Lijnen, E. Maquoi, D. Demeulemeester, B. Van Hoef, and D. Collen Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity Thromb Haemost 88 2002 345 353 (Pubitemid 34873719)
20. I. Scroyen, L. Cosemans, and H.R. Lijnen Effect of tissue inhibitor of matrix metalloproteinases-1 on in vitro and in vivo adipocyte differentiation Thromb Res 124 2009 578 583
21. D. Demeulemeester, D. Collen, and H.R. Lijnen Effect of matrix metalloproteinase inhibition on adipose tissue development Biochem Biophys Res Commun 329 2005 105 110 (Pubitemid 40255427)
22. V.A. Belo, D.C. Souza-Costa, C.M. Lana, F.L.D. Caputo, A.M. Marcaccini, and R.F. Gerlach Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents Clin Biochem 42 2009 984 990
23. B. Głowińska-Olszewska, and M. Urban Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents Metabolism 56 2007 799 805 (Pubitemid 46734087)
24. W. Kosmala, R. Plaksej, M. Przewlocka-Kosmala, J. Kuliczkowska-Plaksej, G. Bednarek-Tupikowska, and W. Mazurek Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function Int J Obes 32 2008 763 771 (Pubitemid 351670619)
25. G. Derosa, I. Ferrari, A. D'Angelo, C. Tinelli, S.A. Salvadeo, and L. Ciccarelli Matrix metalloproteinase-2 and -9 levels in obese patients Endothelium 15 2008 219 224
26. C. Ress, A. Tschoner, C. Ciardi, M.W. Laimer, J.W. Engl, and W. Sturm Influence of significant weight loss on serum matrix metalloproteinase (MMP)-7 levels Eur Cytokine Netw 21 2010 65 70
27. D. Papazoglou, K. Papatheodorou, N. Papanas, T. Papadopoulos, T. Gioka, and G. Kabouromiti Matrix metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 levels in severely obese patients: what is the effect of weight loss? Exp Clin Endocrinol Diabetes 118 2010 730 734
28. E.L. Madsen, J.M. Bruun, K. Skogstrand, D.M. Hougaard, T. Christiansen, and B. Richelsen Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects Metabolism 58 2009 946 953
29. R. Unal, A. Yao-Borengasser, V. Varma, N. Rasouli, C. Labbate, and P.A. Kern Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone Clin Endocrinol Metab 95 2010 2993 3001
30. A. Papazafiropoulou, D. Perrea, I. Moyssakis, A. Kokkinos, N. Katsilambros, and N. Tentolouris Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus J Diabetes Complications 24 2010 20 27
31. A.K. Death, E.J. Fisher, K.C. McGrath, and D.K. Yue High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes Atherosclerosis 168 2003 263 269 (Pubitemid 36703325)
32. F.M. Ho, S.H. Liu, W.W. Lin, and C.S.J. Liau Opposite effects of high glucose on MMP-2 and TIMP-2 in human endothelial cells Cell Biochem 101 2007 442 450 (Pubitemid 46698877)
33. G. Mohammad, and R.A. Kowluru Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction Lab Invest 90 2010 1365 1372
34. R.A. Kowluru, and M. Kanwar Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2 Free Radic Biol Med 46 2009 1677 1685
35. S. Uemura, H. Matsushita, W. Li, A.J. Glassford, T. Asagami, and K.H. Lee Diabetes mellitus enhances vascular matrix metalloproteinase activity role of oxidative stress Circ Res 88 2001 1291 1298 (Pubitemid 32587846)
36. S. Tarallo, E. Beltramo, E. Berrone, P. Dentelli, and M. Porta Effects of high glucose and thiamine on the balance between matrix metalloproteinases and their tissue inhibitors in vascular cells Acta Diabetol 47 2010 105 111
37. P.R. Maxwell, P.M. Timms, S. Chandran, and D. Gordon Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes Diabet Med 18 2001 777 780 (Pubitemid 32953782)
38. N.J. Van der Zijl, R. Hanemaaijer, M.E. Tushuizen, R.K. Schindhelm, J. Boerop, and C. Rustemeijer Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: a marker of incipient diabetic nephropathy? Clin Biochem 43 2010 635 639
39. K.M. Thrailkill, R.C. Bunn, C.S. Moreau, G.E. Cockrell, P.M. Simpson, and H.N. Coleman Matrix metalloproteinase-2 dysregulation in type 1 diabetes Diabetes Care 30 2007 2321 2326 (Pubitemid 47359041)
40. G. Derosa, A. D'Angelo, F. Scalise, M.A. Avanzini, C. Tinelli, and E. Peros Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome Heart Vessels 22 2007 361 370 (Pubitemid 350201431)
41. T. Ishibashi, M. Kawaguchi, K. Sugimoto, H. Uekita, N. Sakamoto, and K. Yokoyama Advanced glycation end product-mediated matrix metalloproteinases-9 and apoptosis via renin-angiotensin system in type 2 diabetes J Atheroscler Thromb 17 2010 578 589
42. A. Mohajerani, A. Ghahary, M. Khuramizadeh, and B. Larijani Serum 14-3-3; matrix metalloproteinases and their inhibitors' levels before and after cardiovascular surgery in diabetic and non-diabetic patients Diabetes Res Clin Pract 90 2010 305 311
43. M. Kamioka, T. Ishibashi, K. Sugimoto, H. Uekita, R. Nagai, and N. Sakamoto Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signalling pathways J Atheroscler Thromb 17 2010 590 600
44. G. Derosa, A. D'Angelo, L. Ciccarelli, M.N. Piccinni, F. Pricolo, and S. Salvadeo Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension Endothelium 13 2006 227 231 (Pubitemid 44110588)
45. V. Fontana, P.S. Silva, V.A. Belo, R.C. Antonio, C.S. Ceron, and C. Biagi Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target Basic Clin Pharmacol Toxicol 2011 10.1111/j.1742-7843. 2011.00698.x
46. J. Tan, Q. Hua, X. Xing, J. Wen, R. Liu, and Z. Yang Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension Hypertens Res 30 2007 959 963 (Pubitemid 350120974)
47. S. Zhou, J. Feely, J.P. Spiers, and A. Mahmud Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension J Hum Hypertens 21 2007 861 867 (Pubitemid 350020338)
48. M. Flamant, S. Placier, C. Dubroca, B. Esposito, I. Lopes, and C. Chatziantoniou Role of matrix metalloproteinases in early hypertensive vascular remodelling Hypertension 50 2007 212 218 (Pubitemid 46986043)
49. M.M. Castro, J.E. Tanus-Santos, and R.F. Gerlach Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension Pharmacol Res 2011 10.1016/j.phrs.2011.04.002
50. P. Nagareddy, P. Rajput, H. Vasudevan, B. McClure, U. Kumar, and K. Macleod Inhibition of matrix metalloproteinase-2 improves endothelial function and prevents hypertension in insulin resistant rats Br J Pharmacol 2011 10.1111/j.1476-5381.2011.01583.x (Jul 8)
51. R.S. Friese, F. Rao, S. Khandrika, B. Thomas, M.G. Ziegler, and G.W. Schmid-Schonbein Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease Clin Exp Hypertens 31 2009 521 533
52. R. Dhingra, M.J. Pencina, P. Schrader, T.J. Wang, D. Levy, and K. Pencina Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community Circulation 119 2009 1101 1107
53. M. Franz, A. Berndt, A. Altendorf-Hofmann, N. Fiedler, P. Richter, and J. Schumm Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy Eur J Heart Fail 11 2009 1057 1062
54. F.L. Li-Saw-Hee, E. Edmunds, A.D. Blann, D.G. Beevers, and G.H. Lip Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy Int J Cardiol 75 2000 43 47
55. F.M. Khezheva, N.A. Mazur, and V.P. Masenko Metalloproteinase activity of the blood in patients with arterial hypertension with paroxysmal form of atrial fibrillation Kardiologiia 47 2007 10 14
56. M.H. Tayebjee, S.K. Nadar, R.J. MacFadyen, and G.Y. Lip Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension. Relationship to tissue Doppler indices of diastolic relaxation Am J Hypertens 17 2004 770 774 (Pubitemid 39201091)
57. X. Gai, Z. Zhang, Y. Liang, Z. Chen, X. Yang, and J. Hou MMP-2 and TIMP-2 gene polymorphisms and susceptibility to atrial fibrillation in Chinese Han patients with hypertensive heart disease Clin Chim Acta 411 2010 719 724
58. I.K. Onal, B. Altun, E.D. Onal, A. Kirkpantur, S.G. Oz, and C. Turgan Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment Eur J Intern Med 20 2009 369 372
59. B. Schieffer, C. Bunte, J. Witte, K. Hoeper, R.H. Boger, and E. Schwedhelm Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease J Am Coll Cardiol 44 2004 362 368 (Pubitemid 38960662)
60. G. Derosa, P. Maffioli, A. D'Angelo, S.A. Salvadeo, I. Ferrari, and E. Fogari Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia Clin Invest Med 32 2009 E124 E132
61. J.L. Beaudeux, P. Giral, E. Bruckert, M. Bernard, M.J. Foglietti, and M.J. Chapman Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia Atherosclerosis 169 2003 139 146 (Pubitemid 36830932)
62. X.P. Xu, S.R. Meisel, J.M. Ong, S. Kaul, B. Cercek, and T.B. Rajavashisth Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages Circulation 99 1999 993 998 (Pubitemid 29104486)
63. S.D. Zhang, L. Yang, G.L. Yu, M. Sun, and H.Y. Zhou Quantitative ultrasonic integrated backscatter of the intima-media complex, serum level of matrix metalloprotease-9 and simvastatin in hyperlipemia patients Zhong Nan Da Xue Xue Bao Yi Xue Ban 33 2008 160 164
64. S. Jormsjo, C. Whatling, D.H. Walter, A.M. Zeiher, A. Hamsten, and P. Eriksson Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients Arterioscler Thromb Vasc Biol 21 2001 1834 1839 (Pubitemid 34219789)
65. M. El Messal, J.L. Beaudeux, A. Drissi, P. Giral, R. Chater, and E. Bruckert Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia Clin Chim Acta 366 2006 185 189 (Pubitemid 43330981)
66. J. Malik, T. Stulc, and R. Ceska Matrix metalloproteinases in isolated hypercholesterolemia Int Angiol 24 2005 300 303 (Pubitemid 41582341)
67. E. Ercan, I. Tengiz, I. Altuglu, C. Sekuri, E. Aliyev, and H.E. Ercan Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia Kardiol Pol 60 2004 454 458 (Pubitemid 38728940)
68. A. Kalela, R. Laaksonen, T. Lehtimäki, T.A. Koivu, M. Höyhtyä, and T. Janatuinen Effect of pravastatin in mildly hypercholesterolemic young men on serum matrix metalloproteinases Am J Cardiol 88 2001 173 175 (Pubitemid 32607707)
69. K.K. Koh, J.Y. Ahn, D.K. Jin, S.H. Han, H.S. Kim, and I.S. Choi Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia Int J Cardiol 97 2004 239 244 (Pubitemid 39286842)
70. K.K. Koh, J.W. Son, J.Y. Ahn, S.K. Hyung, Y.M. Choi, and E.M. Jeong Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease Arterioscler Thromb Vasc Biol 22 2002 e19 e23
71. H.Y. Qu, Y.W. Xiao, G.H. Jiang, Z.Y. Wang, Y. Zhang, and M. Zhang Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia Pharm Res 26 2009 958 964
72. F. Guerrero-Romero, and M. Rodríguez-Morán Concordance between the 2005 International Diabetes Federation definition for diagnosing metabolic syndrome with the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions Diabetes Care 28 2005 2588 2589 (Pubitemid 41384321)
73. J. Hansson, R.S. Vasan, J. Anlov, E. Ingelsson, L. Lind, and A. Larsson Biomarkers of Extracellular Matrix Metabolism (MMP-9 and TIMP-1) and Risk of Stroke, Myocardial Infarction, and Cause-Specific Mortality: Cohort Study PLoS One 6 1 2011 e16185 10.1371/journal.pone.0016185